Express Mail Label No.	EE69	44US	03-	07-01	Cpf	1/1646/\$
CONTINUED PROSECUTION APPLICATION (CPA) REQUES TRANSMITTAL (Larg Entity) Submit an original, and a duplicate for fee processing. (Only for Continuation or Divisional Applications Under 37 CFR 1.53(d))						Ocket No. 11375 ATE (Check box If applicable)
	First Named Inventor Examiner			Group	o/Art Unit	
& TRAD	ouglas, et al.		F. Han	nud	1646	
Address to:  Assistant Commissioner for Patents  Box CPA  Washington, D.C. 20231  This is a request for filing a continuation, or application (CPA)) of prior application number and entitled:  CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER						
1.  Enter the unentered amendment previously filed on under 37 CFR 1.116 in the prior nonprovisional application.						
2. A preliminary am	endment is enclo	sed.				
3. This application is	s being filed by f	ewer than all the	inventors nam	ed in the prior app	olication, 37 CFR 1	.53(d)(4).
	_	nventor(s) name	ed in the prior n	nonprovisional app	lication:	
Rd ustment date: 07/20/2001 6 03/08/2001 SSITHIB1 0000031 1 01 FC:131 710.00 CR 02 FC:103 252.00 CR 03 FC:104 270.00 CR	RELLEY 191013 0905193	<del>}</del>	03/09/ 01 FC: 02 FC: 03 FC:	103 252.0	CH CH	
b. 🗆 The inv	ventor(s) to be de	eleted are set for	th on a separa	te sheet attached	hereto.	
4. A new power of a	ttorney or author	ization of agent	is enclosed.			
5. An Information Di	isclosure Statem	ent (IDS) is encl	osed:	. iquitarija arani	7.	
a. 🗋 PTO-1	449		11	Y 12 1 /4 /4 /4 /4 /4 /4 /4 /4 /4 /4 /4 /4 /4		
b. 🗌 Copies	of IDS Citations	;	03 V2	F65704 5	TOO CH	
6. X The fee for this a	oplication is calc	ulated as follows	): 			
		CLAIMS A	4S FILED			r
For	#Filed	#Allowed	#Extra	Rate	e	Fee
Total Claims	34	- 20 =	14	x \$18.00		\$252.00
Indep. Claims	3	- 3 =	0	x \$78.00		\$0.00
Multiple Dependent Cla	ims (check if	applicable)	X			\$270.00
					BASIC EEE	\$690.00

\$1,212.00

TOTAL FILING FEE

## CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity) (Only for Continuation r Divisi nal Applicati ns Under 37 CFR 1.53(d))

7. 🗷		mmissioner is hereby authorized to credit of Account No. 19-1013/SSMP	overpayments or charge the following fees to		
•/	X	fees required under 37 C.F.R. 1.16. fees required under 37 C.F.R. 1.17. fees required under 37 C.F.R. 1.18.			
. <b>8</b> . 🗆	A check	in the amount of	is enclosed.		
9. 🗆 ,	Also enc	losed:			
:					
<b>\bar{2}</b>					
10. The prior application's correspondence address will carry over to this CPA UNLESS a new correspondence address is provided below:					
			•		

CONTINUED PROSECUTION APPLICATION (CPA) REQUEST TRANSMITTAL (Large Entity)

(Only for C ntinuation or Divisi nal Applications Und r 37 CFR 1.53(d))

## **NOTES**

## Submit an original, and a duplicate for fee processing.

FILING QUALIFICATIONS: The prior application must be a nonprovisional application that is either: (1) complete as defined by 37 C.F.R. 1.51(b), or (2) the national stage of an international application in compliance with 35 U.S.C. 371. A Notice will be placed on a patent issuing from a CPA, except for reissues and designs, to the effect that the patent issued on a CPA and is subject to the twenty-year patent term provisions of 35 USC 154(a)(2). Therefore, the prior application of a CPA may have been filed before, on or after June 8, 1995.

C-I-P NOT PERMITTED: A continuation-in-part application cannot be filed as a CPA under 37 C.F.R. 1.53(d), but must be filed under 37 C.F.R. 1.53(b).

**EXPRESS ABANDONMENT OF PRIOR APPLICATION:** The filing of this CPA is a request to expressly abandon the prior application as of the filing date of the request for a CPA. 37 C.F.R. 1.53(b) must be used to file a continuation, divisional or continuation-in-part of an application that is not to be abandoned.

ACCESS TO PRIOR APPLICATION: The filing of this CPA will be construed to include a waiver of confidentiality by the Applicant under 35 U.S.C. 122 to the extent that any member of the public who is entitled under the provisions of 37 C.F.R. 1.14 to access to, copies of, or information concerning, the prior application may be given similar access to, copies of, or similar information concerning, the other application or application in the file jacket.

35 U.S.C. 120 STATEMENT: In a CPA, no reference to the prior application is needed in the first sentence of the specification and none should be submitted. If a sentence referencing the prior application is submitted, it will not be entered. A request for a CPA is the specific reference required by 35 U.S.C. 120 and to every application assigned the application number identified in such request, 37 C.F.R. 1.78(a).

Dated:	March 5, 2001	JUN Gignature		
		Frank S. DiGiglio		
		Typed or printed name		
		31,346		
		Registration Number (if applicable)		
		☐ Inventor(s)		
		Assignee of complete interest		
		Attorney or agent of record		
CC:				

CERTIFICATE OF	Docket No.					
Applicant(s): Andrea M. Douglas, et al.			14325			
Serial No. Filing Date 09/051,939 October 16, 1998		Examiner	Group Art Unit			
		F. Hamud	1647			
Invention: CYTOKINES AND THEIR USE IN TREATMENT AND/OR PROPHYLAXIS OF BREAST CANCER						
<b>y</b>						
			RECEIVED			
I hereby certify that the following correspondence:			MAR 1 2 2001			
ų.		TECH CENTER 1600/2900				
Continued Prosecution	Continued Prosecution Application (CPA)					
	(Identify type (	of correspondence)				
is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under  37 CFR 1.10 in an envelope addressed to: The Assistant Commissioner for Patents, Washington, D.C. 20231  March 5, 2001  (Date)						
, ,		Frank S. D	iGialin			
Frank S. DiGiglio (Typed or Printed Name of Person Mailing Correspondence)						
(Signature of Person Mailing Correspondence)						
EL835917404US						
("Express Mail" Mailing Label Number)						
Note: Each paper must have its own certificate of mailing.						